Page 6 - ஹெப்ரான் பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
VHIO-born spin-off receives approval to initiate Phase I/II clinical trial of novel Myc inhibitor
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
March 17, 2021
Getting patients with acute ischemic stroke treated more rapidly either through the use of a mobile stroke unit or by taking them directly to the angiography suite increases the number of patients who receive proven therapies and improves clinical outcomes, show two trials presented during the virtual International Stroke Conference 2021 this week.
In the BEST-MSU study, patients initially treated in a mobile stroke unit equipped with mobile CT and able to administer tissue plasminogen activator (tPA) were more likely to receive it within the first “golden hour” and had better functional outcomes at 90 days compared with patients taken to the hospital in a standard ambulance, James Grotta, MD (Memorial Hermann – Texas Medical Center, Houston), reported.
Immune Cells in Cerebrospinal Fluid Predict Response of Brain Metastasis to Immunotherapy
March 9, 2021
Studies by researchers at the Vall d’Hebron Institute of Oncology (VHIO), and the National Centre for Genomic Analysis-Centre for Genomic Regulation (CNAG-CRG), Barcelona, have demonstrated how immune cells that access the cerebrospinal fluid (CSF) of patients with brain metastases faithfully recapitulate the characteristics of the brain tumor immune cells, and could represent novel biomarkers of response to immune checkpoint inhibitor (ICI) therapy.
The team used single-cell RNA sequencing combined with T cell receptor genotyping to characterize immune cells in brain lesions and matched CSF. The single-cell profiling allowed them to chart the major cell types and transient tumor-sepcific states in the brain metastasis (BrM) tumor microenvironment (TME). Describing their results in
Immune Cells in Brain Predict Response to Immunotherapy by Angela Mohan on March 8, 2021 at 6:18 PM
Immune cells accessing cerebrospinal fluid recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies, as per the study in
Nature Communications, led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor.
Immune checkpoint inhibitors including anti-PD1, anti-PD-L1, and anti-CTLA4, have shown significant clinical benefits in patients with progressive or metastatic solid tumors, including some brain metastasis.
Notably, these immune-based therapies have improved outcomes for some of those suffering from lung cancer and melanoma. Together, these tumor types (represent between 30-40% of all cancers), along with breast cancer, are three common malignancies that lead to brain metastases.
vimarsana © 2020. All Rights Reserved.